Hemophagocytic Lymphohistiocytosis (HLH) in a Patient with Disseminated Histoplasmosis.
Neeraja SwaminathanJorge M ViniciusJesse SerrinsPublished in: Case reports in hematology (2020)
Hemophagocytic lymphohistiocytosis (HLH) is a rare condition characterized by an overwhelming inflammatory cascade activation which is often associated with rapid progression and high mortality. It may be familial with an underlying genetic mutation or triggered by infection, malignancy, and autoimmune disease. Disseminated histoplasmosis caused by histoplasma capsulatum is a granulomatous fungal disease seen typically in immunocompromised patients with varied clinical manifestations and requires long-term antifungal therapy. We present the case of a 61-year-old immunocompromised female with significant travel history who came with fever, pancytopenia, and liver failure raising suspicion for HLH that prompted a bone marrow biopsy procedure. Hemophagocytic figures consistent with HLH and numerous encapsulated fungi resembling histoplasma were visualized. She was treated with intravenous (IV) liposomal amphotericin B. Etoposide chemotherapy and interleukin-1 (IL-1) antagonist anakinra were deferred in order to limit her immunosuppression, and treatment was focused on antifungal therapy.
Keyphrases
- liver failure
- bone marrow
- candida albicans
- hepatitis b virus
- multiple sclerosis
- mesenchymal stem cells
- oxidative stress
- case report
- high dose
- early onset
- type diabetes
- intensive care unit
- locally advanced
- combination therapy
- newly diagnosed
- stem cells
- radiation therapy
- dna methylation
- rheumatoid arthritis
- interstitial lung disease
- extracorporeal membrane oxygenation
- systemic sclerosis
- smoking cessation
- mechanical ventilation